Base de dados : MEDLINE
Pesquisa : D12.644.400.100 [Categoria DeCS]
Referências encontradas : 1507 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 151 ir para página                         

  1 / 1507 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29200278
[Au] Autor:Kranz M; Viton F; Smarrito-Menozzi C; Hofmann T
[Ad] Endereço:Chair of Food Chemistry and Molecular Sensory Science, Technical University of Munich , Lise-Meitner Strasse 34, D-85354 Freising, Germany.
[Ti] Título:Sensomics-Based Molecularization of the Taste of Pot-au-Feu, a Traditional Meat/Vegetable Broth.
[So] Source:J Agric Food Chem;66(1):194-202, 2018 Jan 10.
[Is] ISSN:1520-5118
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Targeted quantification of 49 basic taste-active molecules, followed by the calculation of dose-over-threshold (DoT) factors, and taste re-engineering experiments revealed minerals, nucleotides/nucleosides, amino acids, organic acids, and carbohydrates as the key compounds of Pot-au-Feu, a traditional broth preparation from beef cuts and vegetables. Moreover, the dipeptide carnosine was identified to be the key inducer for the white-meaty and thick-sour orosensation of the broth, next to anserine and 1-deoxy-d-fructosyl-N-ß-alanyl-l-histidine, the latter of which has been identified for the first time by means of a sensory-guided fractionation. Sensory studies revealed the threshold concentration of carnosine in model broth to decrease by a factor of 5 upon nonenzymatic glycosylation to reach 4.4 mmol/L for its Amadori product 1-deoxy-d-fructosyl-N-ß-alanyl-l-histidine.
[Mh] Termos MeSH primário: Carne/análise
Paladar
Verduras/química
[Mh] Termos MeSH secundário: Animais
Carnosina/análise
Bovinos
Culinária
Aromatizantes/análise
Análise de Alimentos
Glicosilação
Histidina/análise
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Flavoring Agents); 4QD397987E (Histidine); 8HO6PVN24W (Carnosine)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180205
[Lr] Data última revisão:
180205
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171205
[St] Status:MEDLINE
[do] DOI:10.1021/acs.jafc.7b05089


  2 / 1507 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29191451
[Au] Autor:Banerjee S; Sinha K; Chowdhury S; Sil PC
[Ad] Endereço:Division of Molecular Medicine, Bose Institute, P-1/12, CIT Scheme VII M, Kolkata 700054, India.
[Ti] Título:Unfolding the mechanism of cisplatin induced pathophysiology in spleen and its amelioration by carnosine.
[So] Source:Chem Biol Interact;279:159-170, 2018 Jan 05.
[Is] ISSN:1872-7786
[Cp] País de publicação:Ireland
[La] Idioma:eng
[Ab] Resumo:cis-Diamminedichloroplatinum (cisplatin) is an effective chemotherapeutic and is widely used for the treatment of various types of solid tumors. Bio-distribution of cisplatin to other organs due to poor targeting towards only cancer cells constitutes the backbone of cisplatin-induced toxicity. The adverse effect of this drug on spleen is not well characterized so far. Therefore, we have set our goal to explore the mechanism of the cisplatin-induced pathophysiology of the spleen and would also like to evaluate whether carnosine, an endogenous neurotransmitter and antioxidant, can ameliorate this pathophysiological response. We found a dose and time-dependent increase of the pro-inflammatory cytokine, TNF-α, in the spleen tissue of the experimental mice exposed to 10 and 20 mg/kg body weight of cisplatin. The increase in inflammatory cytokine can be attributed to the activation of the transcription factor, NF-ĸB. This also aids in the transcription of other pro-inflammatory cytokines and cellular adhesion molecules. Exposure of animals to cisplatin at both the doses resulted in ROS and NO production leading to oxidative stress. The MAP Kinase pathway, especially JNK activation, was also triggered by cisplatin. Eventually, the persistence of inflammatory response and oxidative stress lead to apoptosis through extrinsic pathway. Carnosine has been found to restore the expression of inflammatory molecules and catalase to normal levels through inhibition of pro-inflammatory cytokines, oxidative stress, NF-ĸB and JNK. Carnosine also protected the splenic cells from apoptosis. Our study elucidated the detailed mechanism of cisplatin-induced spleen toxicity and use of carnosine as a protective agent against this cytotoxic response.
[Mh] Termos MeSH primário: Antineoplásicos/toxicidade
Carnosina/farmacologia
Cisplatino/toxicidade
Baço/efeitos dos fármacos
Esplenopatias/induzido quimicamente
[Mh] Termos MeSH secundário: Animais
Carnosina/administração & dosagem
Regulação da Expressão Gênica/efeitos dos fármacos
Masculino
Camundongos
Óxido Nítrico/sangue
Baço/fisiopatologia
Esplenopatias/prevenção & controle
Fator de Necrose Tumoral alfa/genética
Fator de Necrose Tumoral alfa/metabolismo
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antineoplastic Agents); 0 (Tumor Necrosis Factor-alpha); 31C4KY9ESH (Nitric Oxide); 8HO6PVN24W (Carnosine); Q20Q21Q62J (Cisplatin)
[Em] Mês de entrada:1801
[Cu] Atualização por classe:180103
[Lr] Data última revisão:
180103
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171202
[St] Status:MEDLINE


  3 / 1507 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27777064
[Au] Autor:Ahshin-Majd S; Zamani S; Kiamari T; Kiasalari Z; Baluchnejadmojarad T; Roghani M
[Ad] Endereço:Neurophysiology Research Center, Shahed University, Tehran, Iran.
[Ti] Título:Carnosine ameliorates cognitive deficits in streptozotocin-induced diabetic rats: Possible involved mechanisms.
[So] Source:Peptides;86:102-111, 2016 Dec.
[Is] ISSN:1873-5169
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Diabetic patients are at increased risk to develop cognitive deficit and senile dementia. This study was planned to assess the benefits of chronic carnosine administration on prevention of learning and memory deterioration in streptozotocin (STZ)-diabetic rats and to explore some of the involved mechanisms. Rats were divided into 5 groups: i.e., control, carnosine100-treated control, diabetic, and carnosine-treated diabetics (50 and 100mg/kg). Carnosine was injected i.p. at doses of 50 or 100mg/kg for 7 weeks, started 1 week after induction of diabetes using streptozotocin. Treatment of diabetic rats with carnosine at a dose of 100mg/kg at the end of the study lowered serum glucose, improved spatial recognition memory in Y maze, improved retention and recall in elevated plus maze, and prevented reduction of step-through latency in passive avoidance task. Furthermore, carnosine at a dose of 100mg/kg reduced hippocampal acetylcholinesterase (AChE) activity, lowered lipid peroxidation, and improved superoxide dismutase (SOD) activity and non-enzymatic antioxidant defense element glutathione (GSH), but not activity of catalase. Meanwhile, hippocampal level of nuclear factor-kappaB (NF-κB), tumor necrosis factor α (TNF-α), and glial fibrillary acidic protein (GFAP) decreased and level of nuclear factor (erythroid-derived 2)-like 2 (Nrf2) and heme oxygenase 1 (HO-1) increased upon treatment of diabetic group with carnosine at a dose of 100mg/kg. Taken together, chronic carnosine treatment could ameliorate learning and memory disturbances in STZ-diabetic rats through intonation of NF-κB/Nrf2/HO-1 signaling cascade, attenuation of astrogliosis, possible improvement of cholinergic function, and amelioration of oxidative stress and neuroinflammation.
[Mh] Termos MeSH primário: Carnosina/farmacologia
Transtornos Cognitivos/prevenção & controle
Diabetes Mellitus Experimental/tratamento farmacológico
Fármacos Neuroprotetores/farmacologia
[Mh] Termos MeSH secundário: Animais
Carnosina/uso terapêutico
Cognição/efeitos dos fármacos
Transtornos Cognitivos/etiologia
Diabetes Mellitus Experimental/complicações
Avaliação Pré-Clínica de Medicamentos
Hipocampo/efeitos dos fármacos
Hipocampo/metabolismo
Masculino
Aprendizagem em Labirinto
Fármacos Neuroprotetores/uso terapêutico
Estresse Oxidativo
Ratos Wistar
Estreptozocina
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Neuroprotective Agents); 5W494URQ81 (Streptozocin); 8HO6PVN24W (Carnosine)
[Em] Mês de entrada:1712
[Cu] Atualização por classe:171219
[Lr] Data última revisão:
171219
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:161030
[St] Status:MEDLINE


  4 / 1507 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28834691
[Au] Autor:Vistoli G; Colzani M; Mazzolari A; Gilardoni E; Rivaletto C; Carini M; Aldini G
[Ad] Endereço:Department of Pharmaceutical Sciences, Università degli Studi di Milano, via Mangiagalli 25, 20133, Milan, Italy.
[Ti] Título:Quenching activity of carnosine derivatives towards reactive carbonyl species: Focus on α-(methylglyoxal) and ß-(malondialdehyde) dicarbonyls.
[So] Source:Biochem Biophys Res Commun;492(3):487-492, 2017 Oct 21.
[Is] ISSN:1090-2104
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:The study combines HPLC-based with MS-based competitive analyses to evaluate the quenching activity of a set of carnosine derivatives towards methylglyoxal (MGO) and malondialdehyde (MDA) chosen as representative of α- and ß-dicarbonyls, respectively. The obtained results underline that these derivatives are moderately reactive towards MDA with which they form the corresponding N-propenal adduct via Michael addition. In contrast they proved a rather poor quenching activity towards MGO with which they can condense to give MOLD-like adducts through a concerted mechanism involving more quenchers molecules. Even though both quenching mechanisms involve the amino group in its neutral form, in silico studies revealed that the reported reactivity values depend on different stereo-electronic parameters which are reflected in the different observed quenching mechanism. Finally, the MGO quenching reactivity and the unselective (and unwanted) pyridoxal quenching are found to be influenced by the same parameters thus rationalizing the known difficulty in the design of potent and selective quenchers towards ß-dicarbonyls.
[Mh] Termos MeSH primário: Carnosina/química
Malondialdeído/química
Aldeído Pirúvico/química
[Mh] Termos MeSH secundário: Cromatografia Líquida de Alta Pressão
Espectrometria de Massas
Estrutura Molecular
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
4Y8F71G49Q (Malondialdehyde); 722KLD7415 (Pyruvaldehyde); 8HO6PVN24W (Carnosine)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171024
[Lr] Data última revisão:
171024
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170824
[St] Status:MEDLINE


  5 / 1507 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28536640
[Au] Autor:Strzemecki D; Guzowska M; Grieb P
[Ad] Endereço:Department of Experimental Pharmacology, Mossakowski Medical Research Centre, Polish Academy of Sciences, 5 Pawinskiego Str., Warsaw, 02-106 Poland.
[Ti] Título:Survival rates of homozygotic knockout rats as a tool for preclinical assessment of cancer prevention and treatment.
[So] Source:Cell Mol Biol Lett;22:9, 2017.
[Is] ISSN:1689-1392
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: The gene that encodes tumor protein p53, , is mutated or silenced in most human cancers and is recognized as one of the most important cancer drivers. Homozygotic 53 knockout mice, which develop lethal cancers early in their lives, are already used in cancer prevention studies, and now 53 knockout rats have also been generated. This study assessed feasibility of using homozygous knockout rats to evaluate the possible outcome of cancer chemoprevention. METHODS: A small colony of 53 knockout rats with a Wistar strain genetic background was initiated and maintained in the animal house at our institution. heterozygotic females were bred with homozygous knockout males to obtain a surplus of knockout homozygotes. To evaluate the reproducibility of their lifespan, 4 groups of homozygous knockout male rats born during consecutive quarters of the year were kept behind a sanitary barrier in a controlled environment until they reached a moribund state. Their individual lifespan data were used to construct quarterly survival curves. RESULTS: The four consecutive quarterly survival curves were highly reproducible. They were combined into a single "master" curve for use as a reference in intervention studies. The average lifespan of untreated male homozygous knockout rats was normally distributed, with a median of 133 days. Sample size vs. effect calculations revealed that confirming a 20% and 30% increase in the lifespan would respectively require a sample size of 18 and 9 animals (when assessed using the -test with a power of 80% and alpha set at 0.05). As an example, the homozygous knockout rat model was used to test the chemopreventive properties of carnosine, a dipeptide with suspected anticancer properties possibly involving modulation of the mTOR pathway. The result was negative. CONCLUSION: Further evaluation of the homozygous knockout male rat colony is required before it can be confirmed as a viable tool for assessing new methods of cancer prevention or treatment.
[Mh] Termos MeSH primário: Homozigoto
Proteína Supressora de Tumor p53/genética
[Mh] Termos MeSH secundário: Animais
Antineoplásicos/farmacologia
Carnosina/farmacologia
Técnicas de Inativação de Genes
Masculino
Neoplasias/tratamento farmacológico
Neoplasias/metabolismo
Ratos
Taxa de Sobrevida
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antineoplastic Agents); 0 (Tumor Suppressor Protein p53); 8HO6PVN24W (Carnosine)
[Em] Mês de entrada:1708
[Cu] Atualização por classe:170808
[Lr] Data última revisão:
170808
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170525
[St] Status:MEDLINE
[do] DOI:10.1186/s11658-017-0039-z


  6 / 1507 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28475972
[Au] Autor:Grasso GI; Bellia F; Arena G; Satriano C; Vecchio G; Rizzarelli E
[Ad] Endereço:Institute of Biostructure and Bioimaging, National Research Council (CNR), via P. Gaifami 18, 95126, Catania, Italy. Electronic address: gigrasso@unict.it.
[Ti] Título:Multitarget trehalose-carnosine conjugates inhibit Aß aggregation, tune copper(II) activity and decrease acrolein toxicity.
[So] Source:Eur J Med Chem;135:447-457, 2017 Jul 28.
[Is] ISSN:1768-3254
[Cp] País de publicação:France
[La] Idioma:eng
[Ab] Resumo:Increasing evidence is accumulating, showing that neurodegenerative disorders are somehow associated with the toxicity of amyloid aggregates, metal ion dyshomeostasis as well as with products generated by oxidative stress. Within the biological oxidation products, acrolein does have a prominent role. A promising strategy to deal with the above neurogenerative disorders is to use multi-functions bio-molecules. Herein, we show how a class of bio-conjugates takes advantage of the antiaggregating, antioxidant and antiglycating properties of trehalose and carnosine. Their ability to sequester acrolein and to inhibit both self- and metal-induced aggregation is here reported. The copper(II) coordination properties of a new trehalose-carnosine conjugate and the relative antioxidant effects have also been investigated.
[Mh] Termos MeSH primário: Acroleína/antagonistas & inibidores
Peptídeos beta-Amiloides/antagonistas & inibidores
Antioxidantes/farmacologia
Carnosina/farmacologia
Cobre/farmacologia
Compostos Organometálicos/farmacologia
Trealose/farmacologia
[Mh] Termos MeSH secundário: Acroleína/toxicidade
Peptídeos beta-Amiloides/metabolismo
Antioxidantes/síntese química
Antioxidantes/química
Carnosina/química
Cobre/química
Relação Dose-Resposta a Droga
Seres Humanos
Estrutura Molecular
Compostos Organometálicos/síntese química
Compostos Organometálicos/química
Agregados Proteicos/efeitos dos fármacos
Relação Estrutura-Atividade
Trealose/química
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Amyloid beta-Peptides); 0 (Antioxidants); 0 (Organometallic Compounds); 0 (Protein Aggregates); 7864XYD3JJ (Acrolein); 789U1901C5 (Copper); 8HO6PVN24W (Carnosine); B8WCK70T7I (Trehalose)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:170928
[Lr] Data última revisão:
170928
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170506
[St] Status:MEDLINE


  7 / 1507 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28407007
[Au] Autor:Tan B; Luo HQ; Xu H; Lv NH; Shi RH; Luo HS; Li JS; Ren JL; Zou YY; Li YQ; Ji F; Fang JY; Qian JM
[Ad] Endereço:Department of Gastroenterology, Peking Union Medical College Hospital, Chinese Academy of Medical Science & Peking Union Medical College, Beijing, China.
[Ti] Título:Polaprezinc combined with clarithromycin-based triple therapy for Helicobacter pylori-associated gastritis: A prospective, multicenter, randomized clinical trial.
[So] Source:PLoS One;12(4):e0175625, 2017.
[Is] ISSN:1932-6203
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:The efficacy and safety of polaprezinc combined with triple therapy was compared with triple therapy alone in the eradication of Helicobacter pylori. A randomized, parallel-group, open-label, controlled, prospective multicenter study was conducted in 11 cities in China. Treatment-naive patients with H. pylori-associated gastritis were randomly assigned to one of three arms for a 14-day treatment: Arm A triple therapy (omeprazole 20 mg, amoxicillin 1 g, and clarithromycin 500 mg, each twice daily) plus polaprezinc 75 mg twice daily; Arm B triple therapy plus polaprezinc 150 mg twice daily, or Arm C triple therapy alone. The rate of H. pylori eradication was the primary endpoint. Secondary endpoints were symptom improvement and lower incidence of adverse events. 303 patients completed the study- 106, 96, and 101 patients in Arms A, B, and C, respectively. Intention-to-treat (ITT) analysis showed that the rate of H. pylori eradication was significantly higher for Arms A (77.0%) and B (75.9%) compared to Arm C (58.6%) (P < 0.01), whereas there was no difference between Arms A and B (P = 0.90). Per-protocol (PP) analysis showed that the rate of H. pylori eradication was significantly higher for Arms A (81.1%) and B (83.3%) compared to Arm C (61.4%) (P < 0.01), whereas there was no significant difference between Arms A and B (P = 0.62). All three groups reported significant symptom improvement at 7, 14, and 28 days after treatment, compared to baseline (P < 0.0001). The adverse event rate for Arm B (5.1%) was higher than for Arms A (2.8%) (P = 0.04) and C (1.9%) (P = 0.02). There were no serious adverse events in any group. It appears that standard dose polaprezinc combined with triple therapy can significantly improve the H. pylori eradication rate, without an increase in toxicity.
[Mh] Termos MeSH primário: Amoxicilina/administração & dosagem
Carnosina/análogos & derivados
Claritromicina/administração & dosagem
Gastrite/tratamento farmacológico
Infecções por Helicobacter/tratamento farmacológico
Omeprazol/administração & dosagem
Compostos Organometálicos/administração & dosagem
[Mh] Termos MeSH secundário: Adulto
Amoxicilina/farmacologia
Carnosina/administração & dosagem
Carnosina/farmacologia
Claritromicina/farmacologia
Quimioterapia Combinada/métodos
Feminino
Gastrite/microbiologia
Helicobacter pylori/efeitos dos fármacos
Seres Humanos
Análise de Intenção de Tratamento
Masculino
Meia-Idade
Omeprazol/farmacologia
Compostos Organometálicos/farmacologia
Estudos Prospectivos
Resultado do Tratamento
Compostos de Zinco/administração & dosagem
Compostos de Zinco/farmacologia
[Pt] Tipo de publicação:JOURNAL ARTICLE; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL
[Nm] Nome de substância:
0 (Organometallic Compounds); 0 (Zinc Compounds); 0WA1B15A1Z (polaprezinc); 804826J2HU (Amoxicillin); 8HO6PVN24W (Carnosine); H1250JIK0A (Clarithromycin); KG60484QX9 (Omeprazole)
[Em] Mês de entrada:1704
[Cu] Atualização por classe:170504
[Lr] Data última revisão:
170504
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170414
[St] Status:MEDLINE
[do] DOI:10.1371/journal.pone.0175625


  8 / 1507 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28276708
[Au] Autor:Yilmaz Z; Kalaz EB; Aydin AF; Soluk-Tekkesin M; Dogru-Abbasoglu S; Uysal M; Koçak-Toker N
[Ad] Endereço:a Department of Biochemistry , Istanbul Medical Faculty, Istanbul University , Istanbul , Turkey , and.
[Ti] Título:The effect of carnosine on methylglyoxal-induced oxidative stress in rats.
[So] Source:Arch Physiol Biochem;123(3):192-198, 2017 Jul.
[Is] ISSN:1744-4160
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:Methylglyoxal (MG) is generated from glycolytic metabolites, lipid peroxidation, glucose autooxidation and protein glycation. It is a prooxidant inducing oxidative stress and formation of advanced glycation end products (AGE). Effect of carnosine (CAR) as an antioxidant on toxicity due to MG has generated interest. In this study, rats were given incrementally increased doses (100-300 mg/kg) of MG in drinking water for ten weeks. CAR (250 mg/kg i.p.) was administered with MG. Plasma thiobarbituric reactive substances (TBARS), protein carbonyl (PC), advanced oxidation protein products (AOPP) and AGE levels were elevated by MG, and CAR decreased PC, AOPP and AGE levels. MG increased liver reactive oxygen species (ROS), TBARS, PC and AOPP levels, which were decreased by CAR. Thus, in vivo role of CAR on chronic MG administration was observed to suppress the generated hepatic and plasma oxidative stress.
[Mh] Termos MeSH primário: Produtos da Oxidação Avançada de Proteínas/antagonistas & inibidores
Antioxidantes/farmacologia
Carnosina/farmacologia
Produtos Finais de Glicação Avançada/antagonistas & inibidores
Fígado/efeitos dos fármacos
Aldeído Pirúvico/antagonistas & inibidores
[Mh] Termos MeSH secundário: Produtos da Oxidação Avançada de Proteínas/agonistas
Produtos da Oxidação Avançada de Proteínas/metabolismo
Animais
Produtos Finais de Glicação Avançada/agonistas
Produtos Finais de Glicação Avançada/metabolismo
Injeções Intraperitoneais
Peroxidação de Lipídeos/efeitos dos fármacos
Fígado/metabolismo
Masculino
Estresse Oxidativo/efeitos dos fármacos
Carbonilação Proteica
Aldeído Pirúvico/toxicidade
Ratos
Ratos Sprague-Dawley
Espécies Reativas de Oxigênio/agonistas
Espécies Reativas de Oxigênio/antagonistas & inibidores
Espécies Reativas de Oxigênio/metabolismo
Substâncias Reativas com Ácido Tiobarbitúrico/metabolismo
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Advanced Oxidation Protein Products); 0 (Antioxidants); 0 (Glycation End Products, Advanced); 0 (Reactive Oxygen Species); 0 (Thiobarbituric Acid Reactive Substances); 722KLD7415 (Pyruvaldehyde); 8HO6PVN24W (Carnosine)
[Em] Mês de entrada:1705
[Cu] Atualização por classe:171116
[Lr] Data última revisão:
171116
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170310
[St] Status:MEDLINE
[do] DOI:10.1080/13813455.2017.1296468


  9 / 1507 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
Texto completo
[PMID]:28245346
[Au] Autor:Dubois VD; Bastawrous A
[Ad] Endereço:Elective Care Centre, Aintree University Hospital NHS Foundation Trust, Longmore Lane, Liverpool, UK, L9 7AL.
[Ti] Título:N-acetylcarnosine (NAC) drops for age-related cataract.
[So] Source:Cochrane Database Syst Rev;2:CD009493, 2017 02 28.
[Is] ISSN:1469-493X
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Cataract is the leading cause of world blindness. The only available treatment for cataract is surgery. Surgery requires highly-trained individuals with expensive operating facilities. Where these are not available, patients go untreated. A form of treatment that did not involve surgery would be a useful alternative for people with symptomatic cataract who are unable or unwilling to undergo surgery. If an eye drop existed that could reverse or even prevent progression of cataract, then this would be a useful additional treatment option.Cataract tends to result from oxidative stress. The protein, L-carnosine, is known to have an antioxidant effect on the cataractous lens, so biochemically there is sound logic for exploring L-carnosine as an agent to reverse or even prevent progression of cataract. When applied as an eye drop, L-carnosine cannot penetrate the eye. However, when applied to the surface of the eye, N-acetylcarnosine (NAC) penetrates the cornea into the front chamber of the eye (near to where the cataract is), where it is metabolised into L-carnosine. Hence, it is possible that use of NAC eye drops may reverse or even prevent progression of cataract, thereby improving vision and quality of life. OBJECTIVES: To assess the effectiveness of NAC drops to prevent or reverse the progression of cataract. SEARCH METHODS: We searched CENTRAL (which contains the Cochrane Eyes and Vision Trials Register) (2016, Issue 6), Ovid MEDLINE, Ovid MEDLINE In-Process and Other Non-Indexed Citations, Ovid MEDLINE Daily, Ovid OLDMEDLINE (January 1946 to June 2016), Embase (January 1980 to June 2016), Allied and Complementary Medicine Database (AMED) (January 1985 to June 2016), Cumulative Index to Nursing and Allied Health Literature (CINAHL) (1982 to June 2016), the ISRCTN registry (www.isrctn.com/editAdvancedSearch), ClinicalTrials.gov (www.clinicaltrials.gov) and the World Health Organization (WHO) International Clinical Trials Registry Platform (ICTRP) (www.who.int/ictrp/search/en). We did not use any date or language restrictions in the electronic searches for trials. We last searched the electronic databases on 28 June 2016. We handsearched the American Society of Cataract and Refractive Surgery (ASCRS) and the European Society of Cataract and Refractive Surgeons (ESCRS) meetings from 2005 until September 2015. SELECTION CRITERIA: We planned to include randomized or quasi-randomised controlled trials where NAC was compared to control in people with age-related cataract. DATA COLLECTION AND ANALYSIS: We used standard methodological procedures expected by Cochrane. MAIN RESULTS: We identified two potentially eligible studies from Russia and the United States. One study was split into two arms: the first arm ran for six months, with two-monthly follow-up; the second arm ran for two years with six-monthly follow-up. The other study ran for four months with a data collection point at the start and end of the study only. A total of 114 people were enrolled in these studies. The ages ranged from 55 to 80 years.We were unable to obtain sufficient information to reliably determine how both these studies were designed and conducted. We have contacted the author of these studies, but have not yet received a reply. Therefore, these studies are assigned as 'awaiting classification' in the review until sufficient information can be obtained from the authors. AUTHORS' CONCLUSIONS: There is currently no convincing evidence that NAC reverses cataract, nor prevents progression of cataract (defined as a change in cataract appearance either for the better or for the worse). Future studies should be randomized, double-masked, placebo-controlled trials with standardised quality of life outcomes and validated outcome measures in terms of visual acuity, contrast sensitivity and glare, and large enough to detect adverse effects.
[Mh] Termos MeSH primário: Carnosina/análogos & derivados
Catarata/tratamento farmacológico
[Mh] Termos MeSH secundário: Idoso
Idoso de 80 Anos ou mais
Envelhecimento
Carnosina/administração & dosagem
Catarata/etiologia
Progressão da Doença
Seres Humanos
Meia-Idade
Soluções Oftálmicas/administração & dosagem
Ensaios Clínicos Controlados Aleatórios como Assunto
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T; REVIEW
[Nm] Nome de substância:
0 (Ophthalmic Solutions); 0TPN86OQIF (N-acetylcarnosine); 8HO6PVN24W (Carnosine)
[Em] Mês de entrada:1706
[Cu] Atualização por classe:170922
[Lr] Data última revisão:
170922
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170301
[St] Status:MEDLINE
[do] DOI:10.1002/14651858.CD009493.pub2


  10 / 1507 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28183595
[Au] Autor:Ketabi S; Rahmani L
[Ad] Endereço:Department of Chemistry, East Tehran Branch, Islamic Azad University, Tehran, Iran. Electronic address: sepidehketabi@yahoo.com.
[Ti] Título:Carbon nanotube as a carrier in drug delivery system for carnosine dipeptide: A computer simulation study.
[So] Source:Mater Sci Eng C Mater Biol Appl;73:173-181, 2017 Apr 01.
[Is] ISSN:1873-0191
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Ab] Resumo:Biological application of carbon nanotube in drug delivery is our main concern in this investigation. For this purpose interaction of carnosine and carbon nanotube was studied in both gas phase and separately in aqueous media. Three possible interactions of carnosine dipeptide with (5,5) carbon nanotube in physiological media were considered. At first step each species were modeled using quantum mechanical calculations, in the next step, their properties in aqueous solution were studied by applying Monte Carlo simulations. The results of density functional calculations in gas phase showed that interaction of zwitterion of carnosine with carbon nanotube via NH had relatively higher interaction energy than the other complexes. Computation of solvation free energies in water showed functionalization with carnosine enhanced the solubility of carbon nanotube significantly that improve the medicinal applications of these materials. Calculation of complexation free energies indicated that zwitterion of carnosine with carbon nanotube via NH produced the most stable complex in aqueous solution. This tendency could be observed in gas and liquid phase similarly.
[Mh] Termos MeSH primário: Carnosina/administração & dosagem
Simulação por Computador
Portadores de Fármacos/química
Sistemas de Liberação de Medicamentos
Nanotubos de Carbono/química
[Mh] Termos MeSH secundário: Carnosina/química
Dipeptidases/química
Método de Monte Carlo
Teoria Quântica
Soluções
Solventes
Termodinâmica
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Drug Carriers); 0 (Nanotubes, Carbon); 0 (Solutions); 0 (Solvents); 8HO6PVN24W (Carnosine); EC 3.4.13.- (Dipeptidases); EC 3.4.13.18 (aminoacyl-histidine dipeptidase)
[Em] Mês de entrada:1706
[Cu] Atualização por classe:170903
[Lr] Data última revisão:
170903
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170211
[St] Status:MEDLINE



página 1 de 151 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde